GleamWall
中文EN

ROIV Roivant Sciences Ltd.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1635088 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY102.1%
TTM net income YoY7.9%
TTM EPS YoY-5.5%
Revenue 3-yr CAGR-16.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,358.1%
Net margin-838.2%
FCF margin-81.2%
EBITDA margin-1,352.0%

Returns

ROE-8.2%
ROA-6.9%
ROIC (approx.)-16.0%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets7.6%
Debt / equity0.00x
Current ratio15.56x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.11x
Accruals ratio-6.1%
Payout ratio—
Capex / revenue-7.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-09-302026Q12026-06-302025Q4*2026-03-312025Q32025-12-312025Q22025-09-302025Q12025-06-302024Q4*2025-03-312024Q32024-12-31
Income statement
Revenue$35.12M$1.44M$2.52M$2.00M$1.57M$2.17M$7.57M$9.02M
Cost of revenue$3.35M———$111,000———
Gross profit$31.77M———$1.46M———
R&D expense$145.75M$202.02M$198.94M$165.38M$164.57M$152.92M$145.24M$141.59M
SG&A expense$154.08M$165.53M$158.25M$175.07M$143.12M$134.02M$147.09M$141.54M
Operating income-$268.05M-$365.99M$415.24M-$339.15M-$306.23M-$284.92M-$284.96M-$274.38M
Pretax income-$166.34M-$294.56M$454.10M-$290.37M-$159.04M-$269.26M-$203.05M-$234.51M
Income tax-$13.37M-$3.96M$98.35M$23.33M$7.00M$4.65M$49.32M-$25.57M
Net income-$191.62M-$189.84M$302.99M-$265.89M-$113.52M-$223.35M-$206.47M$169.38M
EBITDA-$267.44M-$365.39M$415.88M-$338.46M-$305.31M-$283.82M-$283.54M-$271.46M
EPS (basic)-0.27-0.26—-0.38-0.17-0.33—0.23
EPS (diluted)-0.27-0.26—-0.38-0.17-0.33—0.23
Weighted avg. shares (diluted)722.75M720.78M—696.86M680.95M680.29M—722.72M
Balance sheet
Cash & equivalents$1.64B$1.25B$1.42B$1.48B$1.24B$1.24B$2.72B$1.99B
Short-term investments$2.57B$2.59B$2.87B$3.05B$3.15B$3.26B$2.17B$3.16B
Receivables———————$678,000
Current assets$4.36B$4.74B$5.17B$4.66B$4.51B$4.62B$5.00B$5.36B
PP&E, net$10.94M$11.32M$11.99M$13.45M$25.67M$14.87M$12.06M$13.56M
Total assets$4.98B$5.31B$5.71B$5.23B$5.06B$5.03B$5.44B$5.79B
Current liabilities$279.91M$283.60M$281.24M$151.96M$133.86M$113.87M$149.41M$141.48M
Total liabilities$380.10M$384.62M$416.27M$251.14M$257.14M$216.70M$249.74M$256.38M
Shareholders' equity$4.02B$4.23B$4.53B$4.27B$4.36B$4.35B$4.69B$5.19B
Shares outstanding723.69M722.67M720.35M709.69M689.70M682.23M695.94M719.63M
Cash flow statement
Operating cash flow$594.42M-$270.50M-$163.82M-$196.48M-$185.66M-$204.38M-$172.56M-$207.25M
Capital expenditure$208,000$419,000$1.26M-$4.93M$7.85M$4.04M$811,000$1.83M
Free cash flow$594.21M-$270.92M-$165.08M-$191.55M-$193.51M-$208.42M-$173.38M-$209.08M
Investing cash flow$42.54M$281.26M$173.49M$109.47M$120.42M-$1.09B$1.07B$454.07M
Financing cash flow-$249.21M-$181.51M-$68.78M$328.19M$62.59M-$187.77M-$177.15M-$272.95M
Depreciation & amortization$604,000$600,000$638,000$691,000$921,000$1.10M$1.43M$2.92M
Stock-based compensation$79.30M$83.34M$77.17M$105.00M$81.82M$82.18M$83.49M$83.68M
Share buybacks$74.47M$206.73M—$0$0$208.29M$295.44M$243.35M

Free plan shows the latest 8 periods; Pro shows all 26 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.